AbbVie Declares Dividend and Announces Share Repurchase Program

PR Newswire/Les Echos/ 
AbbVie Declares Dividend and Announces Share Repurchase Program 
NORTH CHICAGO, III., Feb. 15, 2013 -- The board of directors of AbbVie Inc.
(NYSE: ABBV) declared a quarterly cash dividend and also authorized a share
repurchase program of up to $1 .5 billion of the Company's outstanding common
stock. 
The cash dividend of $0.40 per share is payable May 15, 2013 to stockholders 
of record at the close of business on April 15, 2013. AbbVie was named to the 
S&P 500 Dividend Aristocrats Index, which tracks companies that have annually
increased their dividend for at least 25 consecutive years. AbbVie was 
included as a result of the Index's change in its treatment of spin-off 
companies. 
The share repurchase authorization, which is effective immediately, is 
expected to be completed over a multi-year period and purchases may be made 
from time to time in management's discretion. The share repurchase 
authorization permits shares to be repurchased in open market or private 
transactions, has no time limit and may be discontinued at any time. 
About AbbVie 
AbbVie is a global, research-based biopharmaceutical company formed in 2013
following separation from Abbott. With its 125-year history, the company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of the
world's most complex and serious diseases. In 2013, AbbVie employs 
approximately 21,000 people worldwide and markets medicines in more than 170 
countries. For further information on the company and its people, portfolio 
and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or 
view careers on our Facebook or LinkedIn page. 
Forward-Looking Statements 
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. AbbVie
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect AbbVie's
operations are discussed in the "Risk Factors" section of the Information
Statement attached to our Form 10 Registration Statement, which has been filed
with the SEC, and are incorporated by reference. AbbVie undertakes no 
obligation to release publicly any revisions to forward-looking statements as 
a result of subsequent events or developments, except as required by law.
 

SOURCE AbbVie Inc. 
CONTACT: Media, Adelle Infante, (847) 938-8745, or Investors, Larry Peepo, 
(847) 935-6722 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Feb/15/2013 14:26 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.